Immvira closes USD58m Series B led by Huagai Capital

Immvira officially announced the completion of a 58 million US dollars (400 million yuan) Series B financing round. The round was led by Huagai Capital, with participation from Apricot Capital, Cowin Capital, and GL Ventures, the leading investor in the previous round.

Immvira officially announced the completion of a 58 million US dollars (400 million yuan) Series B financing round. The round was led by Huagai Capital, with participation from Apricot Capital, Cowin Capital, and GL Ventures, the leading investor in the previous round.

Proceeds from this round of financing will be used to advance clinical research on existing product pipeline, pre-clinical research and development of early-stage innovative drugs, and potential domestic and international strategic cooperation.

Immvira was established on May 18, 2015. It was jointly established by six scientists in the field of “oncolysis and immunity” of the United States. The company has carried out innovations in immunotherapy and targeted therapy of herpes oncolytic virus drug development, including five major product lines, covering all types of tumors.

In the meantime, the company successfully developed the freeze-drying technology of oncolytic virus products, which solved the problem of low temperature storage and transportation of products at -80℃.

Grace Zhou, Chairman and CEO of Immvira, said: “The completion of this financing round marks the important milestone for the company to enter the clinical research stage from the pre-clinical product development.”

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/17/immvira-closes-usd58m-series-b-led-by-huagai-capital/.

Leave a Reply

Please Login to Comment